Introduction

1
Colorectal cancer is the second leading cause of cancer deaths in Western countries (1), 2 and is the third leading cause of cancer deaths in Japan, where there were more than 3 43,000 estimated colorectal cancer deaths in 2008 (2). Treatment of colorectal cancer 4 without metastasis is relatively uncomplicated, and a favorable prognosis can be 5 expected for these patients (3, 4) . However, the 5-year survival rate of patients with 6 metastatic colorectal cancer is estimated to be less than 5% (5) , underscoring the 7 importance of early detection. The modality used most commonly for colorectal cancer 8 mass screening is fecal occult blood (FOB) test. Three large randomized trials 9 demonstrated that inclusion of FOB in colorectal cancer screening significantly reduces 10 the rates of colorectal cancer mortality (6) (7) (8) . However, FOB has a relatively high 11 false-positive rate (9, 10), and as a result, a large number of healthy individuals receive 12 radiological or endoscopic re-examination after the FOB test, placing excessive physical 13 and physiological burdens on examiners and examinees, as well as imposing an undue 14 financial burden upon society. The only approved screening alternative to FOB for the 15 diagnosis of colorectal cancer is testing for the tumor marker carcinoembryonic antigen 16 (CEA). Unfortunately, CEA is not useful as a marker for the early detection of 17 colorectal cancer (11). Therefore, it is necessary to identify a new biomarker to 18 supplement these current diagnostic modalities.
19
Alterations in the protein content of clinical samples reflect the dynamic 20 biological changes of patients more directly than changes in mRNA levels (12) .
21
Plasma/serum proteins are thus valuable resources for the discovery of biomarkers with 22 direct clinical application. We previously developed a quantitative proteomics platform, 23 called 2DICAL (13) . This technology is especially advantageous in clinical studies in 24 which a large number of patient samples must be compared. We were able to identify a number of plasma/serum biomarkers with high potential for clinical application using 1 2DICAL (14) (15) (16) (17) (18) . However, the direct analysis of plasma/serum proteins using 2DICAL 2 remains technically challenging. Proteins secreted by cancer cells are considerably 3 diluted in the blood circulation and present only in a low concentration (19, 20) . The 4 concentration of serum/plasma proteins ranges over more than 10 orders of magnitude, 5 and thus the efficient removal of abundant plasma/serum proteins is essential for the 6 detection of low-abundance cancer-related biomarker proteins (21).
7
In this study we applied a high-performance hollow-fiber membrane (HFM) JMS (n = 9), and ONH (n = 5), and healthy controls from NCCH (n = 2), TMUH (n = 9),
18
OMC (n = 6), and ONH (n = 4). The V1 and V2 cohorts comprised 210 and 113 cases, For all the samples used in this study, the same protocol was used for blood 
LC-MS
14
The HFMT-treated samples were digested with sequencing-grade modified trypsin 15 (Promega, Madison, WI) and analyzed in duplicate using a nano-flow high-performance 16 liquid chromatography (HPLC) (NanoFrontier nLC, Hitachi High-technologies, Tokyo, 17 Japan) connected to an electrospray ionization quadrupole time-of-flight (ESI-Q-TOF) 18 mass spectrometer (Q-Tof Ultima, Waters, Milford, MC).
19
MS peaks were detected, normalized, and quantified using the in-house 20 2DICAL software package, as described previously (13) . A serial identification (ID) 21 number was applied to each of the MS peaks detected (1 to 53009). The stability of follows: the human protein database was selected; up to one missed cleavage was 8 allowed; "none" was designated as the enzyme; mass tolerances for precursor and 9 fragment ions were ± 0.6 Da and ± 0.2 Da, respectively; the score threshold was set to P 10 < 0.05 based on the size of the database used in the search. If a peptide matched 11 multiple proteins, the protein name with the highest Mascot score was selected. 
12
The stained slides were scanned on a microarray scanner (InnoScan ® 700AL, 
Results
15
Plasma biomarker discovery by quantitative MS 16 To identify a diagnostic biomarker for patients with colorectal cancer including those 17 with early-stage diseases, we compared the plasma proteomes of 22 colorectal cancer 18 patients with those of 21 healthy controls (Training cohort) using 2DICAL (Table 1) . Table S1 ). We focused attention on in Figure 1C . The differential expression and identification of adipophilin was 10 confirmed by denaturing SDS-PAGE and immunoblotting analyses (Fig. 1D ).
12
Protein microarray validation 13 To further validate the utility of using adipophilin for the diagnosis of colorectal cancer,
14
the relative level of adipophilin in a total of 323 plasma samples was quantified using 15 reverse-phase protein microarrays (Fig. 2) . Quadruplicate spots for representative cases (Fig. 3B) . The colorectal cancer discriminatory power of 23 adipophilin was also apparent in the V2 cohort (P = 0.00009, Fig. 3C and (Fig. 3D) , indicating that plasma adipophilin 15 and CEA have complementary diagnostic utility.
16
Due to the low prevalence of colorectal cancer among an asymptomatic 17 population, a high specificity is required for a screening biomarker. If we defined the Fig. 4A and 4B) . Adipophilin was not expressed in normal 6 epithelial cells of the colorectal mucosa (Fig. 4C) . The expression of adipophilin was 7 clearly diminished in cancer cells invading in a scattered manner (Fig. 4D) , which is 8 consistent with the lack of staining observed in poorly-differentiated tumor samples. In the present study, we first enriched the LMW plasma protein fraction using HFMT,
13
then compared its contents between patients with colorectal cancer and healthy controls 14 using 2DICAL (Fig. 1) poorly-differentiated adenocarcinoma (Fig. 4) . The immunohistochemical data suggest expression in colorectal cancer, however, remains to be determined.
21
The expression of adipophilin is known to be regulated by hypoxia inducible There are some limitations to our study. First, we have no data regarding the alteration of adipocytokine levels can reportedly affect intestinal carcinogenesis (36).
10
Although adipophilin was originally identified as a marker of adipocyte development
11
(27, 37), its relevance to body shape and cachexia remain to be elucidated. Adipophilin difference in age to be negligible.
24
In conclusion, we identified plasma adipophilin as a new tumor marker for colorectal cancer using LMW protein profiling. The increase of plasma adipophilin 1 level in colorectal cancer was validated in two larger cohorts, and the diagnostic power mind, an independent validation study is warranted. 
